Key terms
About IVA
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IVA news
Apr 08
7:32am ET
Inventiva price target raised to $20 from $12 at Canaccord
Apr 08
7:30am ET
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
Apr 04
2:00am ET
Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
Apr 01
6:25am ET
Buy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical Trials
Mar 28
10:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
Mar 27
5:30pm ET
Inventiva SA ADR Announces Optimistic 2023 Results
Mar 20
8:25am ET
Promising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH Treatment
Mar 19
1:25pm ET
Inventiva’s Lanifibranor Shows Promise in NASH and T2D Treatment: A Buy Rating Justified
Mar 19
6:40am ET
Analysts’ Top Healthcare Picks: Inventiva (IVA), Tenaya Therapeutics (TNYA)
Mar 18
5:27pm ET
Inventiva’s LEGEND Trial Shows Promising Results
Mar 18
4:51pm ET
Inventiva announces LEGEND trial meets primary endpoint
Mar 08
10:35am ET
Inventiva’s Clinical Progress and Financial Valuation Reinforce Buy Rating
Mar 08
8:30am ET
Analysts’ Top Healthcare Picks: Inventiva (IVA), IGM Biosciences (IGMS)
Mar 07
6:25pm ET
Inventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising Outlook
Mar 07
5:09pm ET
Inventiva lifts pause on screening for NATiV3 clinical trial
Feb 20
8:55am ET
Inventiva Stock Buy Rating Affirmed Amid Proactive Management and Promising Drug Trials
Feb 20
8:46am ET
Inventiva price target lowered to $22 from $24 at H.C. Wainwright
Feb 16
11:05am ET
Buy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety Record
Feb 16
8:10am ET
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Disc Medicine (IRON) and Ultragenyx Pharmaceutical (RARE)
No recent press releases are available for IVA
IVA Financials
Key terms
Ad Feedback
IVA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IVA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
